JB
JBIO

Julian Baker’s Jade Biosciences JBIO Stock Holding History

Julian Baker’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3M Sell
1,230,426
-410,711
-25% -$8.57M 0.14% 47
2026
Q1 		$23.1M Hold
1,641,137
– – 0.13% 47
2025
Q4 		$25.3M Buy
+1,641,137
New +$19.3M 0.15% 46
2024
Q4 		– Sell
-17,970
Closed -$1.31M – 97
2024
Q3 		$1.31M Hold
17,970
– – 0.01% 84
2024
Q2 		$1.04M Sell
17,970
-30,045
-63% -$19.9M 0.01% 86
2024
Q1 		$49.7M Hold
48,015
– – 0.62% 25
2023
Q4 		$38M Sell
48,015
-8,084
-14% -$4.12M 0.43% 28
2023
Q3 		$26.6M Hold
56,099
– – 0.15% 31
2023
Q2 		$33.7M Hold
56,099
– – 0.19% 32
2023
Q1 		$39.6M Sell
56,099
-383
-0.7% -$318K 0.22% 25
2022
Q4 		$57.9M Sell
56,482
-77
-0.1% -$55.9K 0.35% 23
2022
Q3 		$32.8M Sell
56,559
-2,584
-4% -$1.73M 0.21% 34
2022
Q2 		$32.4M Hold
59,143
– – 0.18% 34
2022
Q1 		$37.9M Buy
59,143
+6,806
+13% +$2.64M 0.22% 38
2021
Q4 		$21.6M Buy
52,337
+5,132
+11% +$2.6M 0.11% 57
2021
Q3 		$34.7M Buy
47,205
+6,389
+16% +$3.58M 0.15% 48
2021
Q2 		$32.6M Buy
+40,816
New +$32.6M 0.14% 52

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Julian Baker's JBIO Position: Q2 2026 in Review

Julian Baker reduced its Jade Biosciences (JBIO) stake by 25% in Q2 2026, selling an estimated $8.57M and leaving 1,230,426 shares worth $27.3M. The position accounts for 0.14% of the portfolio, ranked #47.

Julian Baker first reported a position in JBIO in Q2 2021 and has held it in 17 quarters since. The position peaked at $57.9M in Q4 2022. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Julian Baker held 1,230,426 shares of Jade Biosciences worth $27.3M as of Q2 2026.
  • Julian Baker sold 410,711 Jade Biosciences shares in Q2 2026, an estimated $8.57M.
  • Jade Biosciences made up 0.14% of Julian Baker's portfolio in Q2 2026, its #47 holding.
  • Julian Baker first reported a position in Jade Biosciences in Q2 2021 and has held it in 17 quarters since.
  • Julian Baker's Jade Biosciences position peaked at $57.9M in Q4 2022.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.